Enanta Pharma (ENTA) Misses Q4 EPS by 27c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $1.86, $0.27 worse than the analyst estimate of $2.13. Revenue for the quarter came in at $75.9 million versus the consensus estimate of $73.12 million.

Financial Guidance for Fiscal Year Ending September 30, 2018

• Research and development expense between $90 million and $110 million
• General and administration expense between $22 million and $28 million

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c